MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
Company profile
Ticker
MYOK
Exchange
Website
CEO
Anastasios E. Gianakakos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MyoKardia Inc
SEC CIK
Corporate docs
Subsidiaries
MyoKardia Australia Pty Ltd. • MyoKardia Netherlands B.V. ...
MYOK stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
27 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
POSASR
Automatic shelf registration (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
8-K
Termination of a Material Definitive Agreement
17 Nov 20
SC 14D9/A
Tender offer solicitation (amended)
17 Nov 20
25-NSE
Exchange delisting
17 Nov 20
Transcripts
MYOK
Earnings call transcript
2020 Q2
5 Aug 20
MYOK
Earnings call transcript
2019 Q4
27 Feb 20
MYOK
Earnings call transcript
2019 Q2
7 Aug 19
MYOK
Earnings call transcript
2019 Q1
9 May 19
MYOK
Earnings call transcript
2018 Q4
4 Mar 19
MYOK
Earnings call transcript
2018 Q2
8 Aug 18
MYOK
Earnings call transcript
2018 Q1
8 May 18
MYOK
Earnings call transcript
2017 Q4
8 Mar 18
MYOK
Earnings call transcript
2017 Q3
2 Nov 17
Latest ownership filings
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
27 Nov 20
4
David P Meeker
19 Nov 20
4
Robert Scott McDowell
19 Nov 20
4
Taylor C. Harris
19 Nov 20
4
SUNIL AGARWAL
19 Nov 20
4
William Fairey
19 Nov 20
4
Jake Bauer
19 Nov 20
4
MARK L PERRY
19 Nov 20
4
Kimberly J Popovits
19 Nov 20
4
MARY B CRANSTON
19 Nov 20
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 678.11 mm | 678.11 mm | 678.11 mm | 678.11 mm | 678.11 mm | 678.11 mm |
Cash burn (monthly) | (no burn) | (no burn) | 28.47 mm | 30.57 mm | 9.83 mm | 22.17 mm |
Cash used (since last report) | n/a | n/a | 1.19 bn | 1.28 bn | 412.36 mm | 930.34 mm |
Cash remaining | n/a | n/a | -516.57 mm | -604.96 mm | 265.75 mm | -252.23 mm |
Runway (months of cash) | n/a | n/a | -18.1 | -19.8 | 27.0 | -11.4 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|